Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Agranulocytosis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07918040
Hematological Safety of Dipyrone Versus Paracetamol After Dental Extractions
The goal of this clinical trial is to compare the safety of dipyrone and paracetamol when used for pain relief after dental extractions in adults. The study will focus on changes in blood cell counts and will also evaluate liver and kidney function and possible side effects. The main questions it aims to answer are: * Do dipyrone and paracetamol have different effects on blood cell counts after dental extractions? * Do participants exhibit hepatic and renal alterations? * What side effects do participants experience when taking these medications? Researchers will compare dipyrone and paracetamol to learn more about their safety after dental extractions. Participants will: * Undergo two dental extractions, one during each study period, involving teeth that already need to be removed * Take dipyrone 500 mg or paracetamol 750 mg in a random order, taking two capsules every 6 hours for 7 days during each period * Have at least 21 days between the two study periods * Have three blood collections: one before the first extraction and one on the eighth day after each extraction * Keep a diary of their pain, medication use, and possible side effects * Have their blood pressure checked and attend clinic visits and telephone follow-ups to monitor their health
Gender: All
Ages: 18 Years - 60 Years
Updated: 2026-11-17
1 state
NCT07913529
Time Course of Clozapine-associated Agranulocytosis Over 19 Years
Clozapine is the most effective antipsychotic medication for treatment-resistant schizophrenia, but it carries a rare, potentially life-threatening risk of agranulocytosis (a severe drop in white blood cells), which is why patients undergo regular blood monitoring. Most cases occur in the first months of treatment, and it remains unclear how much risk persists after the first year. This retrospective study will use existing electronic health records from Sheba Medical Center (February 2007 to August 2026) to describe when agranulocytosis occurs among approximately 2,020 patients treated with clozapine over up to 19 years of follow-up. The study will estimate the cumulative incidence and incidence rates across follow-up periods, examine whether risk after the first 18 weeks remains stable over time, and assess age, sex and psychiatric diagnosis as predictors. Each case will be individually reviewed to distinguish clozapine-related events from neutropenia due to cancer or chemotherapy. No patients will be contacted and no treatment will be changed. The findings are intended to inform policy on long-term hematological monitoring of clozapine-treated patients.
Gender: All
Updated: 2026-11-03
1 state